Responses
Psoriatic arthritis
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study
Compose a Response to This Article
Other responses
No responses have been published for this article.